



US009636389B2

(12) **United States Patent**  
**Fachinger et al.**

(10) **Patent No.:** US 9,636,389 B2  
(45) **Date of Patent:** May 2, 2017

(54) **EFFECTIVE METHOD OF TREATMENT OF PORCINE CIRCOVIRUS AND *LAWSONIA INTRACELLULARIS* INFECTIONS**

(71) Applicant: **Boehringer Ingelheim Vetmedica, Inc.**, Saint Joseph, MO (US)

(72) Inventors: **Vicky Fachinger**, Bad Soden (DE); **Knut Elbers**, Mittelbiberach (DE)

(73) Assignee: **Boehringer Ingelheim Vetmedica, Inc.**, St. Joseph, MO (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/811,313**

(22) Filed: **Jul. 28, 2015**

(65) **Prior Publication Data**

US 2015/0320853 A1 Nov. 12, 2015

**Related U.S. Application Data**

(63) Continuation of application No. 12/518,355, filed as application No. PCT/US2007/025419 on Dec. 11, 2007, now abandoned.

(60) Provisional application No. 60/869,512, filed on Dec. 11, 2006.

(51) **Int. Cl.**

*A61K 39/12* (2006.01)

*A61K 39/02* (2006.01)

*C12N 7/00* (2006.01)

*A61K 39/00* (2006.01)

(52) **U.S. Cl.**

CPC ..... *A61K 39/02* (2013.01); *A61K 39/105*

(2013.01); *A61K 39/12* (2013.01); *C12N 7/00*

(2013.01); *A61K 2039/552* (2013.01); *A61K*

*2039/70* (2013.01); *C12N 2750/10034*

(2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,026,543 A	6/1991	Rijke
5,155,037 A	10/1992	Summers
5,202,430 A	4/1993	Brian et al.
5,322,774 A	6/1994	Peakman et al.
5,436,001 A	7/1995	Kramer
5,565,205 A	10/1996	Petersen et al.
5,580,557 A	12/1996	Kramer
5,733,555 A	3/1998	Chu
5,885,823 A	3/1999	Knittel et al.
5,925,359 A	7/1999	Van Woensel et al.
5,968,525 A	10/1999	Fitzgerald et al.
6,217,883 B1	4/2001	Allan et al.
6,287,856 B1	9/2001	Poet et al.
6,294,176 B1	9/2001	Cochran et al.
6,368,601 B1	4/2002	Allan et al.

6,391,314 B1	5/2002	Allan et al.
6,497,883 B1	12/2002	Bublot et al.
6,517,843 B1	2/2003	Ellis et al.
6,660,272 B2	12/2003	Allan et al.
6,703,023 B1	3/2004	Jestin et al.
6,794,163 B2	9/2004	Liu et al.
6,808,900 B2	10/2004	Simonsen
6,841,364 B2	1/2005	Yuan et al.
6,846,477 B2	1/2005	Keich et al.
6,943,152 B1	9/2005	Audonnet et al.
6,953,581 B2	10/2005	Allan et al.
7,018,638 B2	3/2006	Chu et al.
7,109,025 B1	9/2006	Eloit et al.
7,122,192 B2	10/2006	Allan et al.
7,144,698 B2	12/2006	Wang et al.
7,148,015 B2	12/2006	Jestin et al.
7,169,394 B2	1/2007	Chu et al.
7,172,899 B2	2/2007	Liu et al.
7,179,472 B2	2/2007	Jestin et al.
7,192,594 B2	3/2007	Haines et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2264953 A1	2/1998
CA	2305623 A1	4/1999

(Continued)

OTHER PUBLICATIONS

Weibel et al., "A field efficacy study with Enterisol® Ileitis and Ingelvac CircoFLEX® in Switzerland". Poster Presentations, Porcine Circovirus Associated Diseases (PCVAD-Control) (p. 113), Proceedings of the 21st IPVS Congress, Vancouver, Canada, Jul. 18-21, 2010, p. 419.

Pyle et al., "Secretion of biologically active human proapolipoprotein A-I in a baculovirus-insect cell system: protection from degradation by protease inhibitors". Journal of Lipid Research, vol. 36, 1995, pp. 2355-2361.

Boisgerault et al., "Virus-like particles: a new family of delivery systems". Expert Review of Vaccines, vol. 1, No. 1, Jun. 2002, pp. 101-109.

Weingartl et al., "Porcine circovirus structure and replication: a minireview". Agriculture, vol. 1, 2002, pp. 11-14.

(Continued)

*Primary Examiner* — Shanon A Foley

(74) *Attorney, Agent, or Firm* — Michael P. Morris; Wendy M. Gombert

(57) **ABSTRACT**

The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and *Lawsonia intracellularis* (*L. intracellularis*) antigen for the prevention, reduction in severity of, lessening of the clinical symptoms associated therewith, reduced incidence in a herd, and treatment of swine against Porcine Circovirus Associated Diseases (PCVAD) and *L. intracellularis* associated diseases. In particular, the present invention provides a method for the treatment or prophylaxis of an animal against PCV2 infection and ileitis caused by *L. intracellularis*, or a method for reduction of clinical symptoms caused by or associated with a PCV2 and *L. intracellularis* infection, comprising the step of administering an effective amount of PCV2 antigen and *L. intracellularis* antigen to an animal in need of such treatment.

22 Claims, No Drawings